7月10日，Liquidia盘中下跌5.66%，报76.84美元/股，成交额2070.57万美元。
消息面上，美银证券此前将Liquidia评级从"买入"下调至"中性"，目标价79美元。与此同时，公司董事Bloch Stephen M近期持续大规模减持，仅6月至7月初累计卖出超30万股，套现金额超2200万美元，频繁的内部人减持进一步加剧市场抛压。当前股价已跌破美银目标价，显示市场情绪偏弱。
基本面方面，公司一季度EPS为0.52美元，超市场预期；核心产品YUTREPIA一季度净销售约1.3亿美元，患者覆盖超3750人，商业化进展良好，但短期估值修复受制于评级下调与高管减持双重压力。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.